Financial PositionThe company has $152 million in cash and cash equivalents, providing a substantial financial cushion.
Mergers And AcquisitionsJazz announced that it intends to acquire Chimerix for a value of $8.55/share, a deal that makes strategic sense given Jazz's interest in the oncology/rare disease space.
Regulatory ApprovalThe FDA has accepted Chimerix's NDA with priority review status for dordaviprone, indicating a strong potential for approval.